Background This systematic review and meta-analysis aimed to investigate the clinical
efficacy and safety of novel lipoglycopeptides in treating acute bacterial skin and skin …

Treatment of serious gram‐positive infections presents multiple challenges. Treatment often
results in prolonged hospitalization for administration of intravenous antimicrobials and …

Acute bacterial skin and skin-structure infections (ABSSSIs) are frequent clinical
presentations to emergency departments (EDs) across the nation that can require …

Abstract Purpose of Review The standard of care for serious Gram-positive bacterial
infections, such as osteomyelitis and infective endocarditis, has traditionally required …

Objective: The objective was to conduct a systematic review and network meta-analysis
(NMA) of existing treatments for ABSSSI focusing on the novel lipoglycopeptide oritavancin …

Acute bacterial skin and skin structure infections (ABSSSIs) are some of the most commonly
encountered infections worldwide. Hospitalizations as a result of ABSSSIs are associated …

This article was written with the aim to establish a consensus clinical pathway for long-acting
lipoglycopeptide antibiotics such as oritavancin (Orbactiv®) and dalbavancin (Dalvance®) …

ABSTRACT Introduction Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) are a
common reason of Emergency Department (ED) access and account for a considerable …

Oritavancin is a lipoglycopeptide antibiotic that has been shown to be effective for the
treatment of acute bacterial skin and skin structure infections (ABSSSIs). This antibiotic has …

Background Long-acting lipoglycopeptides (laLGPs) are FDA approved only for acute
bacterial skin and skin structure infections (ABSSSIs). However, these antibiotics show …